Amfil Technologies Inc. $AMFE
AMFE Amfil Technologies Inc. Stock Message Board
I am the Owner/Admin of Investors Hangout and do not trades stocks!
Just doing what I do best, music and coding. I like Honeypots.
A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....
Continue Reading
Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...
Continue Reading
Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...
Continue Reading
Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....
Continue Reading
RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...
Continue Reading
A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...
Continue Reading
A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...
Continue Reading
A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...
Continue Reading
Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...
Continue Reading
A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....
Continue Reading
New York Times Positioned for Future Profit Growth Recently, Deutsche Bank has taken a significant step by initiating coverage on shares of the New York Times (NYSE:NYT) with a promising Buy rating and a price target of $65.00. Their analysis highlights the media company's innovative digital-first subscription model and strong fundamentals as major drivers of growth and...
Continue Reading
Understanding the Current U.S. Commercial Insurance Landscape In today’s economic climate, U.S. commercial insurance buyers are navigating one of the most advantageous periods witnessed in recent years. Despite this promising environment, the looming uncertainties affecting the economy pose challenges that require careful consideration from both buyers and insurers...
Continue Reading
Key Information About Dowlais Group Plc This disclosure pertains to an exempt principal trader engaged in client-serving transactions involving Dowlais Group Plc, providing essential insights into the movements and transactions related to its shares. Notable Dealings by the Exempt Principal Trader As highlighted, important dealings regarding the ordinary shares of Dowlais...
Continue Reading
Golden State Dermatology Welcomes Todd Anhalt The Bay Area’s dermatology landscape just got an intriguing development. Todd Anhalt, a veteran dermatologist with a track record as long as a roll of duct tape, has teamed up with Golden State Dermatology (GSD). This Los Altos partnership isn't just about slapping a new name on a door—it's a strategic move to bolster...
Continue Reading
Tesla got itself into a tight spot back in the day, trading around 40% lower than its peak. Folks were already getting antsy about where the stock was heading—had to keep an eye on those quarterly delivery numbers. The car side of things? Over 80% of projected revenues for FY24 came straight from that segment, so if it tanked, so did the whole show. Tesla's Valuation...
Continue Reading